报价延迟最少15分钟:2026/01/07 16:04 EST
盘后时段
|
||||
|
12.14 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.17
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.09/-1.85
|
|
企业价值
406.50M
|
| 资产负债 |
|
每股账面净值
2.76
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
829.13K
|
|
每股收益
0.00
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder. |
